Adenovirus-mediated Double Suicide Gene Selectively Kills Gastric Cancer Cells

Luo, Xian-Run; Li, Jiansheng; Niu, Yingjie; Li, Miao

doi:10.7314/apjcp.2012.13.3.781

Cited by 10 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study lung cancer cell lines were used along with a carcinoembryonic antigen (CEA) promoter with Thymidine Kinase and Cytosine Deaminase constructing the pCEA-TK/CD [34]. Dual suicide gene therapy has been investigated with surviving promoter Ad-survivin/GFP and Ad-survivin/CD/TK and as anticipated higher efficiency was observed compared to single suicide gene therapy [83]. Moreover; combination suicide gene therapy has been investigated with (VSV)-ΜΔ51-expressing (CD::UPRT)-5FC in four different cancer cell lines (Prostate PC3, Breast MCF7, TSA mammary, Adenocarcinoma, B-Lymphoma Karpas-422, and Melanoma B16-F10) and as a result increased tumor oncolysis was observed [84].…”

Section: Discussionmentioning

confidence: 99%

Gene Therapy for Hepatocellular Carcinoma: An Update

Kosmıdis¹,

Koimtzis²,

Pantos³

et al. 2019

J. Biomed

View full text Add to dashboard Cite

Current statistics indicate that hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related death. Major predisposing conditions are hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. To date treatment approach includes liver transplantation, surgical resection and or ablation, however; recurrence, metastasis, and mortality still remains high. Therefore, alternative treatments such as gene therapy is increasingly being considered as a feasible proposal. In this mini review we will focus on novel data of the past 10 years on the subject of gene therapy and hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Gene Therapy for Hepatocellular Carcinoma: An Update

Kosmıdis¹,

Koimtzis²,

Pantos³

et al. 2019

J. Biomed

View full text Add to dashboard Cite

show abstract

“…Dual suicide gene therapy was also used in lung cancer cell lines with a carcinoembryonic antigen (CEA) promoter with TK and CD constructing the pCEA-TK/CD 42. Dual suicide gene therapy was also investigated with surviving promoter with Ad-survivin/GFP and Ad-survivin/CD/TK 70. A very important parameter that has to be presented is the fact that the pro-drug has to be already diffused within the target tissue prior the administration of the adenovirus in order for the therapy to be efficient.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Suicide Gene Therapy with Adenosine Deaminase 5-Fluorocytosine Silmutaneously in in Vitro Cultures of Melanoma and Retinal Cell Lines

Sakkas¹,

Domvri²,

Hohenforst-Schmidt³

et al. 2014

J. Cancer

View full text Add to dashboard Cite

Local treatment as a treatment modality is gaining increased general acceptance over time. Novel drugs and methodologies of local administration are being investigated in an effort to achieve disease local control. Suicide gene therapy is a method that has been investigated as a local treatment with simultaneously distant disease control. In our current experiment we purchased HTB-70 (melanoma cell line, derived from metastatic axillary node) and CRL-2302 (human retinal epithelium) were from ATCC LGC Standards and Ancotil®, 2.5 g/250 ml (1 g/00ml) (5-Flucytosine) MEDA; Pharmaceuticals Ltd. UK. Adenosine Cytosine Deaminase (Ad.CD) was also used in order to convert the pro-drug 5-Flucytosine to the active 5-Fluoracil. Three different concentrations of 5-Flucytosine (5-FC) were administered (0.2ml, 0.8ml and 1.2ml). At indicated time-points (4h, 8h and 24h) cell viability and apoptosis were measured. Our concept was to investigate whether suicide gene therapy with Ad. CD-5-FC could be used with safety and efficiency as a future local treatment for melanoma located in the eye cavity. Indeed, our results indicated that in every 5-FC administration had mild cytotoxicity for the retinal cells, while increased apoptosis was observed for the melanoma cell line.

show abstract

“…The same technique was again used in lung cancer cell lines with a carcinoembryonic antigen (CEA) promoter with TK and CD constructing the pCEA-TK/CD [29]. Dual suicide gene therapy was also investigated with surviving promoter with Ad-survivin/GFP and Ad-survivin/CD/TK and higher efficiency was observed again with the dual in comparison to single suicide gene therapy [62]. …”

Section: Discussionmentioning

confidence: 99%

“…Another method was to combine the UPRT with the yeast enzymatic activities of CD [28]. Finally, the combination of both systems delivered simultaneously has also been achieved [62,29]. Furthermore, there are other systems that are not widely used such as: a) Varicella-Zoster virus thymidine kinase (VZV-tk), b) Purine nucleoside phosphorylase (PNP) , c) Carboxypeptidase A, d) Carboxypeptidase G2, e) Linamarase, f) Beta-Galatosidase, g) Nitroreductase and h) Hepatic cytochrome P450-2B1…”

Section: Basic Strategies To Induce Cancer Cell Suicidementioning

confidence: 99%

Suicide Gene Therapy for Cancer; Old Dog New Tricks

Zarogoulidis

Darwiche

Sakkas³

et al. 2013

J Genet Syndr Gene Ther

View full text Add to dashboard Cite

Current cancer treatments may create profound iatrogenic outcomes. The adverse effects of these treatments still remain, as the serious problems that practicing physicians have to cope with in clinical practice. Although, non-specific cytotoxic agents constitute an effective treatment modality against cancer cells, they also tend to kill normal, quickly dividing cells. On the other hand, therapies targeting the genome of the tumors are both under investigation, and some others are already streamlined to clinical practice. Several approaches have been investigated in order to find a treatment targeting the cancer cells, while not affecting the normal cells. Suicide gene therapy is a therapeutic strategy, in which cell suicide inducing transgenes are introduced into cancer cells. The two major suicide gene therapeutic strategies currently pursued are: cytosine deaminase/5-fluorocytosine and the herpes simplex virus/ganciclovir. The novel strategies include silencing gene expression, expression of intracellular antibodies blocking cells’ vital pathways, and transgenic expression of caspases and DNases. We analyze various elements of cancer cells’ suicide inducing strategies including: targets, vectors, and mechanisms. These strategies have been extensively investigated in various types of cancers, while exploring multiple delivery routes including viruses, non-viral vectors, liposomes, nanoparticles, and stem cells. We discuss various stages of streamlining of the suicide gene therapy into clinical oncology as applied to different types of cancer. Moreover, suicide gene therapy is in the center of attention as a strategy preventing cancer from developing in patients participating in the clinical trials of regenerative medicine. In oncology, these clinical trials are aimed at regenerating, with the aid of stem cells, of the patients’ organs damaged by pathologic and/or iatrogenic factors. However, the stem cells carry the risk of neoplasmic transformation. We discuss cell suicide inducing strategies aimed at preventing stem cell-originated cancerogenesis.

show abstract

Adenovirus-mediated Double Suicide Gene Selectively Kills Gastric Cancer Cells

Cited by 10 publications

References 18 publications

Gene Therapy for Hepatocellular Carcinoma: An Update

Gene Therapy for Hepatocellular Carcinoma: An Update

Safety and Efficacy of Suicide Gene Therapy with Adenosine Deaminase 5-Fluorocytosine Silmutaneously in in Vitro Cultures of Melanoma and Retinal Cell Lines

Suicide Gene Therapy for Cancer; Old Dog New Tricks

Contact Info

Product

Resources

About